BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38783256)

  • 1. Real-world efficacy and safety of capecitabine with oxaliplatin in patients with advanced adenocarcinoma of the ampulla of Vater.
    Lee S; Park SJ; Shin K; Hong TH; Kim IH; Lee MA
    BMC Cancer; 2024 May; 24(1):634. PubMed ID: 38783256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
    Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
    Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
    Kim ST; Lee J; Lee KT; Lee JK; Lee KH; Choi SH; Heo JS; Choi DW; Park SH; Park JO; Lim HY; Park YS; Kang WK
    Med Oncol; 2010 Dec; 27(4):1149-54. PubMed ID: 19898973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
    Kim HS; Shin SJ; Kim JH; Kim H; Choi HJ
    Tohoku J Exp Med; 2013 Sep; 231(1):21-8. PubMed ID: 23994910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
    Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
    BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
    Osawa H; Handa N; Minakata K
    Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
    Yoshino T; Yamanaka T; Oki E; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Takeuchi S; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Mizushima T; Saji S; Maehara Y; Ohtsu A; Mori M
    JAMA Oncol; 2019 Nov; 5(11):1574-1581. PubMed ID: 31513248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).
    Kosugi C; Koda K; Denda T; Ishibashi K; Ishida H; Seike K; Sakata H; Yanagisawa S; Miyazaki A; Takayama W; Koike N; Shimizu H; Matsubara H
    Int J Colorectal Dis; 2021 Dec; 36(12):2637-2647. PubMed ID: 34368890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II).
    Hattori N; Nakayama G; Uehara K; Aiba T; Ishigure K; Sakamoto E; Tojima Y; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Nagino M; Kodera Y
    Int J Clin Oncol; 2020 Jan; 25(1):118-125. PubMed ID: 31542847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
    Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
    Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic subtype-based evaluation of recurrence and survival outcomes in patients with adenocarcinoma of the ampulla of Vater.
    Park SJ; Shin K; Hong TH; Lee SH; Kim IH; Kim Y; Lee M
    Sci Rep; 2023 Oct; 13(1):16547. PubMed ID: 37783755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extending chemotherapy with capecitabine following CAPOX chemotherapy improves survival of Stage 3 gastric carcinoma after radical surgery: a 5-year analysis.
    Fei Y; Huang SX; Fei MY; Pan XP
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(21):11344-11349. PubMed ID: 33215454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
    Nakayama G; Takano N; Taniguchi H; Ishigure K; Yokoyama H; Teramoto H; Hashimoto R; Sakai M; Ishiyama A; Kinoshita T; Hayashi N; Nakamura M; Hattori N; Sato Y; Umeda S; Uehara K; Aiba T; Sonohara F; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Murotani K; Ando M; Ando Y; Muro K; Kodera Y
    Eur J Cancer; 2021 Feb; 144():61-71. PubMed ID: 33340853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.